论文部分内容阅读
目的研究Ⅰ型胰岛素样生长因子(IGF-Ⅰ)、Ⅱ型胰岛素样生长因子(IGF-Ⅱ)和胰岛素样生长因子Ⅰ受体(IGF-ⅠR)在中国患者前列腺癌组织中的表达情况及其与前列腺癌生物学行为的关系。方法应用免疫组织化学法检测IGF-Ⅰ、IGF-Ⅱ和IGF-ⅠR在良性前列腺增生及前列腺癌组织中的表达情况,实验所得数据用SPSS 12.0统计软件处理。计数资料采用直接概率法和四格表x~2检验,当n>40但有1≤T<5时,用校正的卡方检验,P<0.05为差异有显著性的标准。Spearman等级相关方法分析免疫组化结果与临床病理因素的关系。结果IGF-Ⅰ在良性前列腺增生和前列腺癌组织中的阳性表达率分别为26.67%(8/30)、65.12%(28/ 43)(P<0.05);IGF-Ⅱ在良性前列腺增生和前列腺癌组织中的表达率分别为36.67%(11/30)、72.09%(31/ 43)(P<0.05);IGF-ⅠR在良性前列腺增生和前列腺癌组织中的表达率分别为:43.33%(13/30)、79.07% (34/43)(P<0.05)。结论IGF-Ⅰ、IGF-Ⅱ和IGF-ⅠR与前列腺癌的发生相关,IGF-Ⅰ、IGF-Ⅱ与前列腺癌的发展呈正相关,IGF-ⅠR与前列腺癌的发展不相关。
Objective To investigate the expression of IGF-Ⅰ, IGF-Ⅱ and IGF-ⅠR in Chinese patients with prostate cancer And the biological behavior of prostate cancer. Methods Immunohistochemistry was used to detect the expression of IGF-Ⅰ, IGF-Ⅱ and IGF-ⅠR in benign prostatic hyperplasia (BPH) and prostate cancer tissues. The experimental data were processed by SPSS 12.0 statistical software. Count data using the direct probability method and the four grid table x ~ 2 test, when n> 40 but 1 ≤ T <5, with the chi-square test, P <0.05 for the difference was significant criteria. Spearman rank correlation analysis of immunohistochemical results and clinicopathological factors. Results The positive rates of IGF-Ⅰin benign prostatic hyperplasia and prostate cancer tissues were 26.67% (8/30) and 65.12% (28/43) respectively (P <0.05). The positive rates of IGF-Ⅱ in benign prostatic hyperplasia and prostate cancer The expression rates of IGF-ⅠR in benign prostatic hyperplasia (BPH) and prostate cancer tissues were 43.33% (13/43) (13/30) /30),79.07% (34/43) (P <0.05). Conclusion IGF-Ⅰ, IGF-Ⅱ and IGF-ⅠR are correlated with the development of prostate cancer. IGF-Ⅰ and IGF-Ⅱ are positively correlated with the development of prostate cancer. IGF-ⅠR is not associated with the development of prostate cancer.